This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (238)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Men's Health  • Prostate Disease  • Oncology  • Prostate Cancer  • Radiation Therapy  • Prognosis/ Outcomes  • Alert me on articles by topic  Social Bookmarking   What's this?

A Multi-institutional Pooled Analysis

William U. Shipley, MD; Howard D. Thames, PhD; Howard M. Sandler, MD; Gerald E. Hanks, MD; Anthony L. Zietman, MD; Carlos A. Perez, MD; Deborah A. Kuban, MD; Steven L. Hancock, MD; Cyndi D. Smith

JAMA. 1999;281:1598-1604.

Context  Prostate-specific antigen (PSA) evaluation leads to the early detection of both prostate cancer and recurrences following primary treatment. Prostate-specific antigen outcome information on patients 5 or more years following treatment is limited and available mainly as single-institution reports.

Objectives  To assess the likelihood and durability of tumor control using PSA evaluation 5 or more years after radical external beam radiation therapy and to identify pretreatment prognostic factors in men with early prostate cancer treated since 1988, the PSA era.

Design and Setting  Retrospective, nonrandomized, multi-institutional pooled analysis of patients treated with external beam radiation therapy alone between 1988 and 1995 at 6 US medical centers. Follow-up lasted up to a maximum of 9 years. Outcome data were analyzed using Cox regression and recursive partitioning techniques.

Patients  A total of 1765 men with stage T1b, T1c, and T2 tumors treated between 1988 and 1995 with external beam radiation. The majority (58%) of patients were older than 70 years and 24.2% had initial PSA values of 20 ng/mL or higher. A minimum of 2 years of subsequent follow-up was required for participation.

Main Outcome Measure  Actuarial estimates of freedom from biochemical failure.

Results  The 5-year estimates of overall survival, disease-specific survival, and the freedom from biochemical failure are 85.0% (95% confidence interval [CI], 82.5%-87.6%), 95.1% (95% CI, 94.0%-96.2%), and 65.8% (95% CI, 62.8%-68.0%), respectively. The PSA failure-free rates 5 and 7 years after treatment for patients presenting with a PSA of less than 10 ng/mL were 77.8% (95% CI, 74.5%-81.3%), and 72.9% (95% CI, 67.9%-78.2%). Recursive partitioning analysis of initial PSA level, palpation stage, and the Gleason score groupings yielded 4 separate prognostic groups: group 1, included patients with a PSA level of less than 9.2 ng/mL; group 2, PSA level of at least 9.2 but less than 19.7 ng/mL; group 3, PSA level at least 19.7 ng/mL and a Gleason score of 2 to 6; and group 4, PSA level of at least 19.7 ng/mL and a Gleason score of 7 to 10. The estimated rates of survival free of biochemical failure at 5 years are 81% for group 1, 69% for group 2, 47% for group 3, and 29% for group 4. Of the 302 patients followed up beyond 5 years who were free of biochemical disease, 5.0% relapsed from the fifth to the eighth year.

Conclusions  Estimated PSA control rates in this pooled analysis are similar to those of single institutions. These rates indicate the probability of success for subsets of patients with tumors of several prognostic category groupings. These results represent a multi-institutional benchmark for evidence-based counseling of prostate cancer patients about radiation treatment.

Author Affiliations: Department of Radiation Oncology, Massachusetts General Hospital, Boston (Drs Shipley and Zietman); Department of Biomathematics, MD Anderson Cancer Center, University of Texas, Houston (Dr Thames and Ms Smith); Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor (Dr Sandler); Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pa (Dr Hanks); Mallinckrodt Institute of Radiology, Washington University, St Louis, Mo (Dr Perez); Department of Radiation Oncology, Eastern Virginia Medical School, Norfolk (Dr Kuban); and Department of Radiation Oncology, Stanford University Medical Center, Palo Alto, Calif (Dr Hancock).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLES

Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Charles R. Pound, Alan W. Partin, Mario A. Eisenberger, Daniel W. Chan, Jay D. Pearson, and Patrick C. Walsh
JAMA. 1999;281(17):1591-1597.
ABSTRACT | FULL TEXT  

May 5, 1999
JAMA. 1999;281(17):1663-1664.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A 64-Year-Old Man With Low-Risk Prostate Cancer: Review of Prostate Cancer Treatment
Sanda and Kaplan
JAMA 2009;301:2141-2151.
ABSTRACT | FULL TEXT  

Expression of Immunosuppresive B7-H3 Ligand by Hormone-Treated Prostate Cancer Tumors and Metastases
Chavin et al.
Clin. Cancer Res. 2009;15:2174-2180.
ABSTRACT | FULL TEXT  

Detecting Trends in Noisy Data Series: Application to Biomarker Series
Bellera et al.
Am J Epidemiol 2008;167:1130-1139.
ABSTRACT | FULL TEXT  

Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors
Sanda et al.
NEJM 2008;358:1250-1261.
ABSTRACT | FULL TEXT  

Decision Analyses in Consideration of Treatment Strategies for Patients with Biochemical Failure After Curative Therapy on Clinically Localized Prostate Cancer in the Prostate-Specific Antigen Era
Shimizu et al.
Jpn J Clin Oncol 2007;0:hym105v1-12.
ABSTRACT | FULL TEXT  

Survival Associated With Treatment vs Observation of Localized Prostate Cancer in Elderly Men
Wong et al.
JAMA 2006;296:2683-2693.
ABSTRACT | FULL TEXT  

Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition
Stephenson et al.
JCO 2006;24:3973-3978.
ABSTRACT | FULL TEXT  

Preoperative Serum Caveolin-1 as a Prognostic Marker for Recurrence in a Radical Prostatectomy Cohort.
Tahir et al.
Clin. Cancer Res. 2006;12:4872-4875.
ABSTRACT | FULL TEXT  

Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes Is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment
Ferrari et al.
JCO 2006;24:3081-3088.
ABSTRACT | FULL TEXT  

Monotherapy with Carbon Ion Radiation for Localized Prostate Cancer
Shimazaki et al.
Jpn J Clin Oncol 2006;36:290-294.
ABSTRACT | FULL TEXT  

Phase II Trial of Celecoxib in Prostate-Specific Antigen Recurrent Prostate Cancer after Definitive Radiation Therapy or Radical Prostatectomy.
Pruthi et al.
Clin. Cancer Res. 2006;12:2172-2177.
ABSTRACT | FULL TEXT  

Endorectal MR Imaging before Salvage Prostatectomy: Tumor Localization and Staging
Sala et al.
Radiology 2006;238:176-183.
ABSTRACT | FULL TEXT  

Role of Salvage Radical Prostatectomy for Recurrent Prostate Cancer After Radiation Therapy
Stephenson and Eastham
JCO 2005;23:8198-8203.
ABSTRACT | FULL TEXT  

Predictors of Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation Therapy
Zhou et al.
JCO 2005;23:6992-6998.
ABSTRACT | FULL TEXT  

Radiation Dose Escalation as Treatment for Clinically Localized Prostate Cancer: Is More Really Better?
DeWeese and Song
JAMA 2005;294:1274-1276.
FULL TEXT  

External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Pisansky
Mayo Clin Proc. 2005;80:883-898.
ABSTRACT  

Case 21-2004 - A 63-Year-Old Man with Metastatic Prostate Carcinoma Refractory to Hormone Therapy
Kaufman et al.
NEJM 2004;351:171-178.
FULL TEXT  

Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy
Stephenson et al.
JAMA 2004;291:1325-1332.
ABSTRACT | FULL TEXT  

Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor {beta}1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression
Shariat et al.
Clin. Cancer Res. 2004;10:1992-1999.
ABSTRACT | FULL TEXT  

Pretreatment Nomogram That Predicts 5-Year Probability of Metastasis Following Three-Dimensional Conformal Radiation Therapy for Localized Prostate Cancer
Kattan et al.
JCO 2003;21:4568-4571.
ABSTRACT | FULL TEXT  

Phase I Study of Replication-Competent Adenovirus-Mediated Double-Suicide Gene Therapy in Combination with Conventional-Dose Three-Dimensional Conformal Radiation Therapy for the Treatment of Newly Diagnosed, Intermediate- to High-Risk Prostate Cancer
Freytag et al.
Cancer Res. 2003;63:7497-7506.
ABSTRACT | FULL TEXT  

Do Older Men Benefit From Curative Therapy of Localized Prostate Cancer?
Alibhai et al.
JCO 2003;21:3318-3327.
ABSTRACT | FULL TEXT  

External Beam Radiation Monotherapy for Localized or Locally Advanced Prostate Cancer
Takahashi et al.
Jpn J Clin Oncol 2003;33:73-77.
ABSTRACT | FULL TEXT  

Determinants of Prostate Cancer-Specific Survival After Radiation Therapy for Patients With Clinically Localized Prostate Cancer
D'Amico et al.
JCO 2002;20:4567-4573.
ABSTRACT | FULL TEXT  

Comparison of Logistic Regression and Neural Net Modeling for Prediction of Prostate Cancer Pathologic Stage
Veltri et al.
Clin. Chem. 2002;48:1828-1834.
ABSTRACT | FULL TEXT  

Comparing the Costs of Radiation Therapy and Radical Prostatectomy for the Initial Treatment of Early-Stage Prostate Cancer
Burkhardt et al.
JCO 2002;20:2869-2875.
ABSTRACT | FULL TEXT  

Comprehensive Comparison of Health-Related Quality of Life After Contemporary Therapies for Localized Prostate Cancer
Wei et al.
JCO 2002;20:557-566.
ABSTRACT | FULL TEXT  

A Phase I Trial of CV706, a Replication-competent, PSA Selective Oncolytic Adenovirus, for the Treatment of Locally Recurrent Prostate Cancer following Radiation Therapy
DeWeese et al.
Cancer Res. 2001;61:7464-7472.
ABSTRACT | FULL TEXT  

Re-irradiation and external hyperthermia in locally advanced, radiation recurrent, hormone refractory prostate cancer: a preliminary report
Kalapurakal et al.
Br. J. Radiol. 2001;74:745-751.
ABSTRACT | FULL TEXT  

Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer
Crook et al.
CMAJ 2001;164:975-981.
ABSTRACT | FULL TEXT  

Preoperative Serum Prostate-specific Antigen (PSA) Below 10 {micro}g/L Predicts Neither the Presence of Prostate Cancer Nor the Rate of Postoperative PSA Failure
Stamey
Clin. Chem. 2001;47:631-634.
ABSTRACT | FULL TEXT  

Progressing Prostate Carcinoma
Haut et al.
The Oncologist 2001;6:183-196.
ABSTRACT | FULL TEXT  

Equivalent Racial Outcome After Conformal Radiotherapy for Prostate Cancer: A Single Departmental Experience
Connell et al.
JCO 2001;19:54-61.
ABSTRACT | FULL TEXT  

Cloning and Characterization of UROC28, a Novel Gene Overexpressed in Prostate, Breast, and Bladder Cancers
An et al.
Cancer Res. 2000;60:7014-7020.
ABSTRACT | FULL TEXT  

Pretreatment Nomogram for Predicting the Outcome of Three-Dimensional Conformal Radiotherapy in Prostate Cancer
Kattan et al.
JCO 2000;18:3352-3359.
ABSTRACT | FULL TEXT